Form 4 for OMCL OMNICELL, INC.
Accepted 2022-03-16 00:00:00 ET · period of report 2022-03-14 · accession 0001179110-22-002278 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-16 | 2022-03-14 | OMCL | Seidelmann Scott Peter | EVP, Chief Commercial Off | A - Grant | $0.00 | +19.0K | 53.1K | +56% | $0 | |
| 2022-03-16 | 2022-03-14 | OMCL | Seidelmann Scott Peter | EVP, Chief Commercial Off | F - Tax | $131.21 | -2,235 | 50.9K | -4% | -$293.3K | |
| 2022-03-16 | 2022-03-16 | OMCL | Seidelmann Scott Peter | EVP, Chief Commercial Off | S - Sale | $133.11 | -2,525 | 48.4K | -5% | -$336.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-14 | A | A | 19,040 | $0.00 | 53,140 | D | — | — | (F1) Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022. |
| 2 | Common | Common Stock | 2022-03-14 | F | D | 2,235 | $131.21 | 50,905 | D | — | — | (F2) Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units. |
| 3 | Common | Common Stock | 2022-03-16 | S | D | 2,525 | $133.11 | 48,380 | D | — | — | (F3) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9,2021. (F4) The price reported in Column 4 is an exact price of $133.11 for all shares sold. |